Biotech Diligence Questions, Red, Green and Checkered Flag Answers
David Sable (Forbes)
The Seven Deadly Sins of Biotech Investing
@bin2gray via Adam Feuerstein (TheStreet)
Two disparate yet enticing follow-ons to the ever popular topic of biotech investing red flags.
NPS Pharma illustrates why breakout rooms should be webcast
Brad Loncar (Loncar Blog)
On one of the largest remaining potential "loopholes" in Reg FD / fair disclosure.
Is this how we'll cure cancer?
Matthew Herper (Forbes)
Print magazine feature on the CAR-T revolution in oncology.
FDA Finalizes Expedited Product Guidance With Hundreds of Major, Minor Changes
Alexander Gaffney (Regulatory Focus)
Guidance document covering Breakthrough therapy designation, Fast Track, Accelerated Approval, and Priority Review.
The Day I Started Lying to Ruth
Peter Bach (New York Magazine)
What Price Innovation? The Sovaldi Saga
John LaMattina (Forbes)
David Sable (Forbes)
The Seven Deadly Sins of Biotech Investing
@bin2gray via Adam Feuerstein (TheStreet)
Two disparate yet enticing follow-ons to the ever popular topic of biotech investing red flags.
NPS Pharma illustrates why breakout rooms should be webcast
Brad Loncar (Loncar Blog)
On one of the largest remaining potential "loopholes" in Reg FD / fair disclosure.
Is this how we'll cure cancer?
Matthew Herper (Forbes)
Print magazine feature on the CAR-T revolution in oncology.
FDA Finalizes Expedited Product Guidance With Hundreds of Major, Minor Changes
Alexander Gaffney (Regulatory Focus)
Guidance document covering Breakthrough therapy designation, Fast Track, Accelerated Approval, and Priority Review.
The Day I Started Lying to Ruth
Peter Bach (New York Magazine)
What Price Innovation? The Sovaldi Saga
John LaMattina (Forbes)
RSS Feed
